TY - JOUR
T1 - Treatment Time or Convection Volume in HDF
T2 - What Drives the Reduced Mortality Risk?
AU - de Roij van Zuijdewijn, Camiel L M
AU - Nubé, Menso J.
AU - ter Wee, Piet M.
AU - Blankestijn, Peter J.
AU - Lévesque, Renée
AU - van den Dorpel, Marinus A.
AU - Bots, Michiel L.
AU - Grooteman, Muriel P C
PY - 2015/8
Y1 - 2015/8
N2 - Background/Aims: Treatment time is associated with survival in hemodialysis (HD) patients and with convection volume in hemodiafiltration (HDF) patients. High-volume HDF is associated with improved survival. Therefore, we investigated whether this survival benefit is explained by treatment time. Methods: Participants were subdivided into four groups: HD and tertiles of convection volume in HDF. Three Cox regression models were fitted to calculate hazard ratios (HRs) for mortality of HDF subgroups versus HD: (1) crude, (2) adjusted for confounders, (3) model 2 plus mean treatment time. As the only difference between the latter models is treatment time, any change in HRs is due to this variable. Results: 114/700 analyzed individuals were treated with high-volume HDF. HRs of high-volume HDF are 0.61, 0.62 and 0.64 in the three models, respectively (p values <0.05). Confidence intervals of models 2 and 3 overlap. Conclusion: The survival benefit of high-volume HDF over HD is independent of treatment time.
AB - Background/Aims: Treatment time is associated with survival in hemodialysis (HD) patients and with convection volume in hemodiafiltration (HDF) patients. High-volume HDF is associated with improved survival. Therefore, we investigated whether this survival benefit is explained by treatment time. Methods: Participants were subdivided into four groups: HD and tertiles of convection volume in HDF. Three Cox regression models were fitted to calculate hazard ratios (HRs) for mortality of HDF subgroups versus HD: (1) crude, (2) adjusted for confounders, (3) model 2 plus mean treatment time. As the only difference between the latter models is treatment time, any change in HRs is due to this variable. Results: 114/700 analyzed individuals were treated with high-volume HDF. HRs of high-volume HDF are 0.61, 0.62 and 0.64 in the three models, respectively (p values <0.05). Confidence intervals of models 2 and 3 overlap. Conclusion: The survival benefit of high-volume HDF over HD is independent of treatment time.
UR - http://www.scopus.com/inward/record.url?scp=84933576186&partnerID=8YFLogxK
U2 - 10.1159/000430903
DO - 10.1159/000430903
M3 - Article
C2 - 26111967
AN - SCOPUS:84933576186
SN - 0253-5068
VL - 40
SP - 53
EP - 58
JO - Blood Purification
JF - Blood Purification
IS - 1
ER -